Christof Schaefer
TIS Berlin
Charité Universitätsmedizin Berlin, Germany
Prof. Dr.med. Christof Schaefer, MD, PhD is a paediatrician and professsor at the Pharmacovigilance and Counseling Center for Embryonic Toxicology (Embryotox) at Charité Universitätsmedizin Berlin.
Prof. Schaefer is founder of the Berlin TIS and one of the founding members of ENTIS. He was for many years board member and member of ENTIS scientific advisory board, and was appointed as President of ENTIS in the period 2006-2009.
He is now a member of the Drug Commission of the German Medical Association, besides beeing member of scientific advisory board/Expert of: European Medicines Agency (EMA), Orphanet network of rare diseases, Boletin del ECEMC, International Lactation Consultants Association (ILCA), Reproductive Toxicology and Arzneimittelbrief (Journal of Independent Drug Information).
Miguel del Campo
Rady Children's Hospital - San Diego
University of California, San Diego School of Medicine
Center for Better Beginnings, USA
Miguel del Campo is a medical geneticist at Rady Children's Hospital-San Diego and an associate professor at UC San Diego.
After graduating from the Universidad Complutense de Madrid in Spain, Dr. del Campo went on to complete additional training at the Hospital Universitario La Paz and the Universidad Autonoma de Madrid. He followed this training with a fellowship in genetics and dysmorphology at the University of California San Diego, a Ph.D. in pediatrics from the Universidad Autonoma de Madrid, and postdoctoral training at the Salk Institute for Biological Studies.
Dr. del Campo cares for patients with dysmorphologic, genetic, and teratologic conditions and his current research interests include: Fetal Alcohol Syndrome (FAS), congenital Zika infection, limb defects and HOX signaling pathways, Williams syndrome, autism, prenatal diagnosis through comparative genomic hybridization, and Marfan syndrome and other connective tissue disorders. Additionally, he actively participates in various national and international organization as well as support groups for parents with children with genetic disorders and FAS disorders.
Matteo Cassina
Clinical Genetics Unit, Department of Women's and Children's health, University of Padova, Italy
Dr. Matteo Cassina is an assistant professor of Medical Genetics at the Department of Women’s and Children’s Health of the University of Padova, Italy; moreover, he is a consultant at the Clinical Genetics Unit and the Teratology Information Service of the University Hospital of Padova.
His key interests include: the genetic bases and clinical phenotype of syndromes with ear malformations; genotype-phenotype correlations in genetic disorders with intellectual disability and congenital malformations; teratogenic risk associated with prenatal exposure to drugs; epidemiology of birth defects.
Olav Spigset
Department of Clinical Pharmacology, St. Olavs Hospital, Trondheim University Hospital, Norway
Olav Spigset, M.D., Ph.D., is senior consultant at the Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway, and professor of clinical pharmacology at the Norwegian University of Science and Technology. His professional work has for more than 25 years been devoted to drug safety, including drug interactions, adverse drug reactions, therapeutic drug monitoring, pharmacokinetics, pharmacogenetics, and drug use in pregnancy and lactation, with a particular focus on psychotropic drugs. He is a member of numerous scientific committees and boards and has published more than 300 scientific articles.
Cecilie Johannessen Landmark
Programme for Pharmacy, Faculty of Health Sciences, OsloMet - Oslo Metropolitan University
National Centre for Epilepsy and Department of Pharmacology, Oslo University Hospital, Norway
MSc. Pharm., PhD, Professor of Pharmacology.
Cecilie Johannessen Landmark has long-term experience with research on clinical pharmacology of antiepileptic drugs and implementation of TDM with focus on special patient groups, pharmacokinetics and drug interactions, as well as pharmacoepidemiology and drug utilisation, aiming at a multidisciplinary approach to research in epilepsy and related disorders. She is a medical adviser at the National center for epilepsy and the leader of the research groups Medicines and patient safety and the group of Clinical pharmacology of antiepileptic drugs and is involved in several international networks and task forces on treatment of epilepsy.
Christina Chambers
University of California, San Diego School of Medicine
Center for Better Beginnings
President OTIS, USA
Dr. Christina Chambers is a Professor in the School of Medicine at UC San Diego. She is Co-Director of the Center for Better Beginnings, Program Director of MotherToBaby, a service providing evidence-based information on exposures during pregnancy and lactation, and is Program Director of Mommy’s Milk, a human milk biorepository for research.
Dr. Chambers leads a number of national and international complex longitudinal cohort studies and clinical trials of prenatal exposures and child health and development. Her research has been instrumental in identifying previously unrecognized human teratogens, as well as ruling out substantial risk for medications and vaccines.
Solveig Thorp Holmsen
National Resources Center for Breastfeeding, Norway
Dr. Solveig Thorp Holmsen graduated from University of Oslo, Faculty of Medicine in 1997. She obtained a Masters degree in Public Health from Johns Hopkins University in 1998. Surgical residency and continuing work in the Oslo Emergency Room a department of Oslo University Hospital since 2001 where she is currently working as a Consultant Doctor. Solveig wanted to offer better treatment to mothers suffering from lactational mastitis in her clinic and to work with the health system to prevent this condition among mothers. She started as a medical advisor in the Norwegian National Advisory Unit on Breastfeeding in 2011 and she is currently specializing in community medicine. She is working on a National level to increase the knowledge on breastfeeding and prevention and treatment of lactational mastitis. She has experience in evaluating and treatment of medical conditions that can be a challenge for breastfeeding. Observing the association between tongue ties and lactational mastitis in her daily practice she started addressing this problem. She is organizing the work developing a knowledge based National guidance document on the diagnosis and treatment of tongue-tie among infants in Norway. She has also received funding for research on tongue-ties in Norwegian infants.
Alice Panchaud
TIS Lausanne, Switzerland
Alice Panchaud, PhD, Privat Docent & Maître d’Enseignement et de Recherche, is a certified clinical pharmacist and pharmacologist trained as a teratogen information service counselor at the University Hospital of Lausanne and at the Hospital for Sick Children in Toronto. She is a lecturer on drug therapy optimization in pregnant and lactating women at the School of Pharmacy of Geneva and Lausanne, the CHUV University Hospital and the Haute Ecole de Santé Vaudoise. Her research interests focus mainly on safety and effectiveness of drugs during pregnancy and lactation using pharmacoepidemiological approaches. Lately, she completed a research fellowship at the Department of Epidemiology, Harvard T.H. Chan School of Public Health in Boston, where she has been working with large administrative databases to pursue her work in the neglected field of drug therapy during pregnancy.
Karel Allegaert
KU Leuven, Belgium
Prof dr Karel Allegaert, is pediatrician-neonatologist and clinical pharmacologist. He is associate Professor (Department of Development and Regeneration, KU Leuven) and consultant (Department of Pediatrics, division Neonatology, Erasmus MC Rotterdam). His clinical research is focussed on perinatal and neonatal clinical pharmacology and the relevant co-variates (maturational, non-maturational, pharmacogenetics, disease-related, pregnancy related), and the subsequent use of in vivo datasets to develop prediction models. More recently, his research further expanded to in vitro models (placenta, renal tubular cells), in vivo models (bronchopulmonary dysplasia rabbit) and long term pharmacovigilance in former preterm neonates.
Orchid profile Research gate profile
Eugene van Puijenbroek
Netherlands Pharmacovigilance Center Lareb, The Netherlands
Eugène van Puijenbroek is a medical doctor and clinical pharmacologist who has been working at the Netherlands Pharmacovigilance Centre Lareb since 1994. He is currently Head of the Science and Research Department. In 2001 he obtained a PhD degree at the Department of Pharmacotherapy and Pharmacoepidemiology at the Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, the Netherlands. Since April 2014 he is professor of pharmacovigilance at the Faculty of Science and Engineering, Department of PharmacoTherapy, -Epidemiology and -Economics of the University of Groningen, the Netherlands. He obtained a vast experience analysing signals in the spontaneous reporting system of the Netherlands and published in national as well as international journals. His current field of attention is the development of signal detection methodologies, especially the integration of the statistical approach combined with the use of clinical information. He has been a member of the executive board of the International Society of Pharmacovigilance from 2006 till 2012 and a co-opted member of the Pharmacovigilance Working Party of the European Medicines Agency from 2010-2012. He is a member of the editorial board of Drug Safety since 2001 and Chair of the Signal Management Review Technical Working Group (SMART WG) meeting – Work stream 2-3 European Medicines Agency. Next to his work in pharmacovigilance he has been working as a general practitioner from 1991 till 2006.
Ilan Matok
Institute for Drug Research, School of Pharmacy, Jerusalem, Israel
Dr. Ilan Matok is an Associate Professor and the head of the Pharmacoepidemiology Research Lab at the Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine at the Hebrew University of Jerusalem, Israel.
Dr. Matok is a clinical pharmacist and his training was in pharmacoepidemiology, specifically on fetal drug safety during pregnancy. He received his PhD from Ben-Gurion University in Israel and he did his post doc fellowship with Dr. Gideon Koren in Sickkids Toronto, and later with Dr. Samy Suissa at McGill university in Montreal.
His group is studying the use, safety and effectiveness of drugs, mainly in special populations (Pregnant women, children and the elderly) by using pharmacoepidemiological research methods, including computerized databases (“big data”) and by using advanced methods of meta-analysis.